PCSK9 Inhibitors and Real-World Evidence

Slides:



Advertisements
Similar presentations
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Advertisements

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.
The Latest Lipid Guidelines:
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
LDL Established Target for Cardiovascular Risk
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Diabetes and Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
PAD Patients vs Post-ACS Patients:
A New Era for NOACs:.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Select Topics in Cardiovascular Medicine
American Heart Association Scientific Sessions
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
Statin Selection in Special Patient Populations: A Case Challenge
What Has Been Tried and What Is True?
Understanding Statin Metabolism
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
Tailoring Antiplatelet Therapy in PCI
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Statin Class in Session
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
PCSK9 Inhibitors and Cardiovascular Outcomes
% decrease in LDL-C at 24 weeks from baseline
A Better Solution For Cancer Patients With VTE?
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
A Patient Journey Through Statin Intolerance
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Exploring Statin Intolerance
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
Monoclonal Antibodies in CVD: What Does the Future Hold?
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
PCSK9 Mutations PCSK9 Loss-of-function Mutations.
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Latest Lipid Guidelines in Perspective
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Reducing Risk for CV Outcomes
Practical Strategies for Getting Patients With Diabetes to Lipid Goal
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
PCSK9 Inhibitors and Statin Intolerance
Achieving Lipid Targets With PCSK9 Inhibition
Lipids, the Heart, and the Kidney
Shared-Decision Making in Dyslipidemia
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

PCSK9 Inhibitors and Real-World Evidence

When to Consider Nonstatin Therapy

Nonstatin Recommendations From Treatment Guidelines

Beyond Statins – AHA/ACC 2018 Lipid Updates

PCSK9 Inhibitors FDA Indications

PCSK9 Inhibitors Dosing and Administration

FOURIER Outcomes Trial Evolocumab

FOURIER Efficacy Outcomes

FOURIER Safety

FOURIER Total Primary Endpoint Events

ODYSSEY Outcomes Study Alirocumab

Alirocumab ODYSSEY Outcomes Trial Results

OSLER-1 Trial

High-Risk Groups for Future ASCVD Events 2018 ACC/AHA Cholesterol Guidelines

FOURIER Trial PAD Subgroup Analysis

Who Will Benefit Most From "Lowest Is Best" Strategy?

Statin-Associated Muscle Symptoms vs Statin Intolerance

Identify Patients With Statin Intolerance

Statins and Glucose Homeostasis Perception vs Evidence

Improving PCSK9 Inhibitor Approval Rates

Navigating the Prior Authorization Process With the Patient

Navigating the Prior Authorization Process Clinical Pearls

Clinical Tips for Therapeutic Management of PCSK9 Inhibitors

Conclusion

Abbreviations

Abbreviations (cont)